In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Eisai buys MGI Pharma

Executive Summary

Japan's Eisai Co. Ltd. (neurology, gastrointestinal, and oncology therapeutics) will buy MGI Pharma (cancer and acute care) for $3.3bn in cash, or $41 for each of MGI's 81mm outstanding shares (a 25% premium).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Full Acquisition
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register